INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial.

PURPOSE To prospectively investigate the injection frequency of aflibercept and ranibizumab in the treatment of macular edema in central retinal vein occlusion. METHODS Patients with treatment-naive central retinal vein occlusion and macular edema were randomized to receive intravitreal injections with aflibercept (n = 22) or ranibizumab (n = 23) in a treat-and-extend regimen with a follow-up time of 18 months. After 3 loading doses, the treatment intervals were extended by 2 weeks to a maximum of 12 weeks. Intervals were shortened by 2 weeks if macular edema recurred. RESULTS The number of injections was significantly lower in the aflibercept group with a mean of 10.9 injections (95% confidence interval, 9.6-12.3) compared with 14.4 in the ranibizumab group (95% confidence interval 12.7-16.1) at study completion (P = 0.0017). The mean treatment interval was significantly longer in the aflibercept group compared with the ranibizumab group 10.0 (95% confidence interval, 8.7-11.3) and 6.6 (95% confidence interval, 5.2-8.0) weeks, respectively (P < 0.001). No significant difference between the groups regarding visual acuity or central retinal thickness was observed. CONCLUSION Patients with macular edema secondary to central retinal vein occlusion required significantly fewer intravitreal injections of aflibercept compared with ranibizumab when treated with a treat-and-extend regimen. This may reduce the treatment burden and, to some extent, the need for close monitoring of patients.

[1]  M. Ohji,et al.  Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion , 2016, Japanese Journal of Ophthalmology.

[2]  M. Ohji,et al.  Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes. , 2015, Investigative ophthalmology & visual science.

[3]  E. Day,et al.  Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. , 2014, Molecular pharmaceutics.

[4]  P. Campochiaro,et al.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. , 2014, Ophthalmology.

[5]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[6]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. , 2013, American journal of ophthalmology.

[7]  Y. Ogura,et al.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study , 2013, British Journal of Ophthalmology.

[8]  J. Haller,et al.  Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. , 2012, Ophthalmology.

[9]  S. Seregard,et al.  Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. , 2012, Ophthalmology.

[10]  M. Michaelis,et al.  Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion , 2012, Acta ophthalmologica.

[11]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[12]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.

[13]  C. Ehlken,et al.  Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion. , 2011, American journal of ophthalmology.

[14]  N. Ferrara,et al.  Comparing protein VEGF inhibitors: In vitro biological studies. , 2011, Biochemical and biophysical research communications.

[15]  S. Hayreh,et al.  Natural history of visual outcome in central retinal vein occlusion. , 2011, Ophthalmology.

[16]  Lois E. H. Smith,et al.  VITREAL LEVELS OF ERYTHROPOIETIN ARE INCREASED IN PATIENTS WITH RETINAL VEIN OCCLUSION AND CORRELATE WITH VITREAL VEGF AND THE EXTENT OF MACULAR EDEMA , 2010, Retina.

[17]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[18]  P. Rosenfeld,et al.  Predicted biological activity of intravitreal VEGF Trap , 2008, British Journal of Ophthalmology.

[19]  P. Mitchell,et al.  Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. , 1996, Archives of ophthalmology.